SMS Pharmaceuticals Intrinsic Value
SMSPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹249.92 | ₹199.94 - ₹299.90 | -27.6% | EPS: ₹11.36, Sector P/E: 22x |
| Book Value Method | asset | ₹862.50 | ₹776.25 - ₹948.75 | +150.0% | Book Value/Share: ₹711.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹690.00 | ₹621.00 - ₹759.00 | +100.0% | Revenue/Share: ₹1084.44, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹690.00 | ₹621.00 - ₹759.00 | +100.0% | EBITDA: ₹200.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹845.86 | ₹676.69 - ₹1015.03 | +145.2% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹103.50 | ₹93.15 - ₹113.85 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹175.51 | ₹157.96 - ₹193.06 | -49.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹690.00 | ₹621.00 - ₹759.00 | +100.0% | ROE: 15.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹426.33 | ₹383.70 - ₹468.96 | +23.6% | EPS: ₹11.36, BVPS: ₹711.11 |
Want to compare with current market value? Check SMSPHARMA share price latest .
Valuation Comparison Chart
SMSPHARMA Intrinsic Value Analysis
What is the intrinsic value of SMSPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of SMS Pharmaceuticals (SMSPHARMA) is ₹690.00 (median value). With the current market price of ₹345.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹103.50 to ₹862.50, indicating ₹103.50 - ₹862.50.
Is SMSPHARMA undervalued or overvalued?
Based on our multi-method analysis, SMS Pharmaceuticals (SMSPHARMA) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.94 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.80 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 15.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for SMS Pharmaceuticals
Additional stock information and data for SMSPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹82 Cr | ₹21 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹50 Cr | ₹24 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹23 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹45 Cr | ₹32 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹90 Cr | ₹14 Cr | Positive Free Cash Flow | 7/10 |